After two and a half years at sea, Flagship Pioneering-backed cell signaling company Sonata Therapeutics is whittling down its crew by about 20 employees, a company spokesperson confirmed to Fierce Biotech in a Nov. 21 email.

LONDON—It’s been a big year for Genmab. While celebrating its 25th anniversary, the cancer-focused biopharma hasn’t rested on its laurels—securing another approval for the AbbVie-partnered Epkinly, scoring its first M&A win and slowly moving from a partner-based to an asset owner-focused model.

Enveda, a company using artificial intelligence to boost nature-based drug discovery, is envisioning clinical success with a $130 million series C fundraising round.

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center to develop new models for lung diseases like pulmonary fibrosis, the researchers announced in an Oct. 17 release.

Supernus Pharmaceuticals has linked its mTORC1 activator to rapid improvements in adults with major depressive disorder (MDD) in a small trial, pointing to one possible path forward for a candidate that is barreling toward phase 2b data in another indication.

Roche has made another MAGE-A4 program disappear, withdrawing a phase 1 trial of a T-cell bispecific prospect before a single patient was enrolled.

Taiwan’s REGiMMUNE and Europe-based Kiji Therapeutics are merging to create a globally minded regulatory T-cell biotech that already has its eyes set on an IPO.

At a town hall featuring FDA leadership at the AdvaMed MedTech Conference in Toronto, Michelle Tarver, M.D., Ph.D., took the time to introduce—or reintroduce—herself to members of the industry, this time as the acting director of the agency’s Center for Devices and Radiological Health.

Terray Therapeutics has raked in $120 million for a series B fundraise as the AI-focused biotech aims to transform small molecule drug development.

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small molecule discovered by a Chinese biotech that has built a business around botanical drugs.